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Abstract 
Background: Treatment outcomes of a high proportion of inpatients with multi-drug resistant tuberculosis (MDR-TB) 
were not reported to the Vietnamese National Tuberculosis Program because they received treatment outside of the 
green light committee (GLC) program. The study aimed (1) to describe the strengths and weaknesses of treatment of 
GLC and non-GLC MDR-TB patients as well as the factors influencing treatment completion and (2) to determine the 
incidence of adverse drug reactions.
Results: This cross-sectional study comprised two elements: (1) in-depth interviews with clinical doctors, hospital 
pharmacists; and focus group discussions with MDR-TB patients; and (2) a review of the charts of all GLC and non-GLC 
MDR-TB patients in 2010. A total of 282 MDR-TB patients were recruited, including 79(28 %) MDR-TB patients treated 
through the GLC program and 203(72 %) MDR-TB patients treated outside of the GLC program. The main strengths 
of GLC treatment were the supply of quality assured second line TB drugs, routine monitoring and clinical evalua-
tion, free diagnostic tests and close clinical monitoring. The greatest barriers to patients treated outside of the GLC 
program was difficulty paying for second line TB drugs and other treatment costs. There was no significant difference 
between the incidence of adverse events among GLC (46.8 %) and non-GLC treated patients (52.2 %; p = 0.417). 
Among 143 patients who reported 226 adverse reaction events, arthralgia/joint pain (35.8 %), gastrointestinal (14.2 %), 
ototoxicity (8.4 %), cutaneous (6.6 %), and giddiness (5.8 %) were the most common.
Conclusions: The non-GLC MDR-TB patients face substantial barriers to treatment, and require greater support if they 
are to complete treatment and improve disease outcomes. Staff training about the management of adverse drug 
reactions is needed.
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Background
Vietnam ranks 12th among the 22 high-TB burden coun-
tries, and is one of the 27 high-multi-drug resistant 
tuberculosis (MDR-TB) burden countries in the world. 
In 2013, the estimated incidence of TB all forms was 
144/100,000 population, and prevalence was 209/100,000 
population and the estimated TB all forms case detection 
rate was 76 % [1].
The most recent national drug resistant survey (DRS) 
in 2011 estimated the prevalence of MDR-TB to be 4 % 
among new patients and 23  % among the previously 
treated cases, which translates to an estimated number 
of 5100 MDR-TB cases per year (3000 new and 2100 re-
treatment cases) [1].
The World Health Organization (WHO) and the 
Stop TB Partnership have been supporting countries 
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to manage multidrug-resistant tuberculosis (MDR-TB) 
through the green light committee (GLC) Initiative, 
providing access to quality-assured second-line anti-TB 
medications under programmatic management condi-
tions [2]. According to the programmatic management of 
drug-resistant TB (PMDT) monitoring report in March 
2012, first-line (FLD) and second-line anti-TB drugs 
(SLDs) of unknown quality are still available in Vietnam. 
The SLDs still are available for purchase in pharmacies 
and chemist shops in local include Kanamycin (Km); 
Levofloxacin (Lfx); Ethionamide (Eto), Cycloserine (Cs) 
and p-aminosalicylic acid (PAS). Many non-GLC drugs 
are imported without being subjected to defined qual-
ity assurance processes. Availability of potentially sub-
standard products to creates the potential for inadequate 
therapies, and an increase in the incidence of extensively 
drug resistant (XDR) TB [3].
In Vietnam, two evaluations of PMDT in February 
2011, and March 2012 revealed that a large proportion 
of MDR-TB patients treated within public lung disease 
hospitals were receiving non-GLC drugs, and that their 
treatment outcomes were often not reported to the 
national tuberculosis programme (NTP) [3]. The second 
evaluation found that in some facilities, MDR patients 
were managed by doctors who had inadequate training 
for PMDT. It also showed that prescribed and self-admin-
istered SLD drugs of undetermined quality were being 
given for prolonged periods. Bacteriologic outcomes and 
documentation of compliance was limited, meaning that 
outcomes could not be evaluated. The report concluded 
that unregulated use of non-standardised drugs and an 
absence of appropriate quality assurance processes out-
side of the Global Fund administered programs may 
compromise patient outcomes [3].
In order to better understand about MDR-TB treat-
ment in public TB/MDR-TB facilities, we conducted a 
study to characterise the perceived strengths and weak-
nesses of treatment for MDR-TB within and outside 
of the GLC program at the largest public TB hospital 
dealing with MDR-TB patients in Ho Chi Minh City 
(HCMC), Vietnam. We also evaluated the incidence of 
adverse drug reactions in this population.
Methods
Study design
This cross-sectional study was carried out in Pham Ngoc 
Thach hospital (PNT), HCMC, Vietnam in 2012; includ-
ing quantitative and qualitative components.
Study participants and sampling
Qualitative component: We conducted four In-depth 
interviews with three MDR-clinical doctors and a 
pharmacist in PNT. Two groups of MDR-TB patients, 
both GLC-approved and non-GLC, have been enrolled 
in this study based on the following criteria: (1) they had 
registered for MDR-TB treatment during the years 2010–
2012; (2) they live near the study hospitals, or are still 
hospitalized for MDR treatment. There were ten patients 
in each group.
Quantitative component: We also extracted informa-
tion of treatment and adverse events among 282 GLC 
and non-GLC MDR-TB patients enrolled for treatment in 
2010, based upon chart review. 79 of them (28 %) belong 
to the GLC MDR-TB patient group and 203 (72  %) of 
them belong to the non-GLC MDR-TB patient group.
Measurement
In this study, we collected data/information from three 
sources: (1) face to face interviews with health staffs (2) 
focus group discussions (FGD) with MDR-TB patients 
and (3) review of patient medical records.
Variables/themes
  • Variables evaluated in the quantitative component: 
The main variable was adverse drug reactions dur-
ing treatment. Information relating to the treatment 
of MDR-TB patients: GLC or non-GLC treatment; 
treatment default; and the MDR-TB treatment regi-
men. We also extracted patients’ gender and age from 
MDR-TB patient charts.
  • Themes from the qualitative component: The 
strengths and weakness of GLC treatment; the bar-
riers to patients treated outside of GLC program; and 
reasons for patients’ choice of either GLC or non-
GLC treatment.
Data collection
Data were collected by a survey team of five members 
from the NTP staff using a check list and semi-structured 
questionnaires. The team was trained to collect data from 
treatment cards and patients’ charts for all MDR-TB 
patients treated in 2010. In-depth interviews and FGDs 
were undertaken by the principal investigator. Data were 
collected during December 2012.
Data entry and analysis
Qualitative data: Data analysis has been done themati-
cally using open coding. Information has been summa-
rized and presented by theme/subthemes.
Quantitative data: Data were entered in an electronic 
data file using EpiData Entry software (http://www.epi-
data.dk) and analyzed using Stata version 10. Hypothesis 
testing was performed using the Chi square tests for the 
difference in proportions with the alpha value of 0.05.
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Ethical issues
Ethical approval was obtained from the Ethical Com-
mittee of the Vietnam National Lung Hospital. Verbal 
consent was obtained from all persons taking part in the 
interview. Information gathered from clinicians, phar-
macists and patient data were kept confidential. Patients’ 
names were not collected.
Results
A total of 282 MDR-TB patients enrolled during 2010 at 
PNT hospital were recruited from patient’s charts. Of 
those 79 (28  %) patients receiving treatment with GLC 
drugs and 203 (72 %) receiving non-GLC MDR-TB drugs. 
Of 282 MDR-TB patients, 182 (65  %) were males, and 
there was no significant difference in the sex distribution 
between the GLC and non-GLC groups (Table  1). The 
majority of MDR-TB patients belonged to the 30–45 age 
group (58 % in GLC group and 60 % in non-GLC group). 
The mean age of 79 GLC patients was 44.3  years old 
(SD = 12.8) and that of 203 non-GLC patients was 40.4 
(SD = 13.2).
Table  1 shows some of the regimens most frequently 
used in the treatment of non-GLC patients. In general, 
the non-GLC patients did not follow regimens 4A and 
4B stated in the Vietnamese national guidelines. Ethiona-
mide was used instead of Prothionamide in the regimen; 
hence, this regimen differs from regimens 4A or 4B.
Reasons for choosing non‑GLC treatment
All of three clinical doctors reported that the main rea-
sons that patients choose the non-GLC treatment were 
that (a) they did not meet criteria for enrolment into the 
GLC program, such as that they were not long-term resi-
dents of HCMC or (b) patients did not accept treatment 
as inpatients.
Attitudes among MDR‑TB patients towards non‑GLC 
and GLC treatments
Among ten MDR-TB patients receiving GLC drugs that 
took part in FGD, seven perceived those drugs to have 
good quality. All of them said that they would receive 
free testing with sputum smear, CXR and culture; eight 
of them perceived they would be monitored closely by 
health staff within official DOTS treatment centres. GLC 
patients had lower default rates than did non-GLC MDR 
patients (5 defaulters out of 79 GLC patients (6.3  %) 
vs. 52 defaulter out of 203 non-GLC patients (25.6  %, 
p < 0.001) Table 1.
Among the group of ten MDR-TB patients who did 
not receive GLC drugs, eight of them made their choice 
because they did not want to travel to health care facili-
ties each day to receive treatment. They were also were 
able to work during treatment (six of them were still 
working during treatment). This was particularly impor-
tant to patients who working far from home, and wealth-
ier patients who did not want to be identified with other 
MDR-TB patients in their neighborhood. In contrast, 
patients receiving GLC treatment needed to attend TB 
daily for 18–24 months so that they could receive inject-
able antibiotics or oral SLDs. This presented a substan-
tial challenge to MDR-TB patients with severe disease, or 
those who were the primary income earners and worked 
far from home.
The greatest challenge for non-GLC MDR-TB patients 
was their ability to pay for SLDs and other expenses, all of 
ten non-GLC MDR-TB patients mentioned about it. Both 
health staff and patients reported that the costs of meals, 
transportation and follow-up tests were substantial over 
the long treatment periods (normally 18–24  months). 
Moreover, as patients self-administered their treatment, 
important ADRs were unlikely to be resolved in a timely 
and safe manner. These factors are likely to contribute to 
the higher default rate seen among non-GLC MDR-TB 
patients.
Table 1 General and  treatment characteristics of  MDR-TB 
patients in GLC and non-GLC groups, in Pham Ngoc Thach 
hospital, 2010
Characteristics GLC (n = 79) Non‑GLC (n = 203) p value
n % n %
Sex
 Male 57 72.2 125 61.6 0.226
 Female 21 26.6 76 37.4
 Unknown 1 1.3 2 1.0
Age groups
 <30 16 20.3 49 24.1
 30–45 46 58.2 122 60.1 0.302
 >45 16 20.3 32 15.8
 No information 1 1.3 0.0
Treatment regimen
 Regimen 4A 43 54.4 1 0.5
 Regimen 4B 34 43.0 0 0.0
 Others 1 1.3 202 99.5
 No information 1 1.3 0 0.0
Treatment outcome
 Cured 62 78.5 99 48.8 <0.001
 Completed 5 6.3 10 4.9
 Failure 2 2.5 5 2.5
 Default 5 6.3 52 25.6 <0.001
 Died 3 3.8 0 0
 Transfer-out 0 0 2 1
 Still on treatment 0 0 1 0.5
 Not evaluated 2 2.5 34 16.8
Page 4 of 6Hoa et al. BMC Res Notes  (2015) 8:809 
Factors influencing treatment completion by MDR patients
The factors associated with not completing treat-
ment among GLC patients included: limited financial 
resources, employment status (i.e., patients have to work 
for living) and the perception that free drugs were of a 
lower quality. Factors that encouraged compliance with 
treatment among GLC patients included provision of 
the drugs free of charge, supervision of therapy, the use 
of treatment supporters (a commune health worker and 
family member), provision of ancillary therapies to treat 
ADRs and a budget to support patients traveling from 
home.
Among non-GLC patients, there was no restriction 
regarding the use of TB drugs, and doctors were unable 
to ensure compliance (i.e., if patients interrupted their 
treatment, doctors were only able to give advice). Other 
reasons for non-compliance included the long dura-
tion of treatment, such that when patients felt better 
they believed that they had been cured and could stop 
treatment.
The non-GLC MDR TB patients have to pay all treat-
ment costs themselves, including expensive SDL. If the 
patients had sufficient resources to afford treatment 
and SLD, they were likely to take the drugs according to 
medical advice. Others factor associated with adherence 
or treatment completion among non-GLC patients were 
their economic status and the presence of strong domes-
tic support for treatment, such as strong family support.
The challenges patients faced during MDR‑TB treatment
Among patients receiving non-GLC treatment, doc-
tors prescribed the SLD regimen for 1  month. Treated 
patients needed to purchase the drugs at the hospital 
pharmacy. Patients were requested to self-administer the 
drugs, and to return to the hospital monthly for a clinical 
check-up, sputum smear and culture. Furthermore, such 
patients were requested to attend to have a chest X-ray 
every 2–3 months.
Non-GLC patients felt most secure receiving treatment 
in the hospital, and accepted the specialist knowledge of 
the doctors. The main reason that patients choose treat-
ment with non-GLC regimens was that they felt they had 
no choice, as they did not meet the required criteria for 
free treatment.
The adverse drugs reaction
Table  2 presents the cumulative incidence of adverse 
drugs events occurring during treatment of GLC and 
non-GLC MDR-TB patients in PNT hospital in 2010. 
There was no significant difference between the inci-
dence of adverse drug events during treatment between 
GLC and non-GLC MDR-TB patients (46.8 vs. 52.2  %, 
p = 0.417).
Among 143 patients who reported 226 adverse reaction 
events, the most common adverse event was arthralgia/
joint pain (35.8  %), followed by gastrointestinal symp-
toms (14.2  %), ototoxicity (8.4  %), cutaneous reactions 
(6.6 %), and dizziness (5.8 %). Among these 226 adverse 
reaction events, 25 were classified as severe, and led to 
a change in regimen or complete cessation of therapy 
(Table 3).
Discussion
The most common reason given by patients for choosing 
non-GLC treatment was that they did not satisfy inclu-
sion criteria for enrolment into GLC program. This was 
often because they were not resident in HCMC, or had 
difficulty in receiving treatment as inpatients. At the time 
of this study (2010), enrolment in the subsidized GLC 
treatment program required that patients were diag-
nosed at PNT hospital or had been referred from one of 
the HCMC district TB units, and that they were official 
residents of HCMC. If they met these criteria, they could 
receive 1–2 months of free inpatient therapy during their 
intensive phase, and subsequent supervised treatment at 
district TB units. Many of these patients were resident 
outside of HCMC, or were required to attend local dis-
trict TB units to receive supervised daily SLD therapy. 
At that time, few other provinces in Vietnam had offered 
subsidized PMDT, including the major cities of HCMC, 
Can Tho, and Ha Noi, as well as Binh Dinh province and 
the northern K74 and K71 hospitals. Other provincial TB 
centers and district TB had not yet received training in 
the management of MDR-TB patients. Hence, few MDR-
TB patients from outside of the selected provinces where 
treatment was offered could access continuous MDR-
TB treatment after their initial inpatient therapy. After 
the year 2011, currently, the NTP has been extended 
PMDT to 10 treatment and 35 satellite sites in 45 prov-
inces. Since that time, a growing number of patients with 
Table 2 Adverse drug events occurred during  treatment 
of  GLC and  non-GLC MDR-TB patients, Pham Ngoc Thach 
hospital, 2010
Adverse drugs event GLC Non‑GLC p value
n % N %
Total 79 100.0 203 100.0 0.417
No adverse events 42 53.2 97 47.8
Adverse events 37 46.8 106 52.2 0.779
 1 event 25 31.6 63 31.0
 2 events 9 11.4 27 13.3
 ≥3 events 3 3.8 16 7.9
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MDR-TB patients have been able to satisfy the criteria for 
subsidized MDR therapy.
The most substantial part of MDR-TB treatment is the 
cost of drugs. Expensive drugs must be taken for a long 
duration (18  months), and ongoing laboratory tests, 
travel expenses, examination fees and other costs are 
beyond the financial means of many patients. This likely 
explains much of the high drop-out rate from non-GLC 
therapy. In the future, drug costs and additional financial 
supplements will be required to reduce the default rate 
and reduce the substantial difference in treatment com-
pletion between GLC and non-GLC MDR-TB patients.
The official guidelines for MDR-TB treatment by the 
Vietnam NTP at the time of the study was a 4A regimen 
for new cases [6 Z E Km Lfx Pto Cs (PAS)/12 Z E Lfx Pto 
Cs (PAS)] and a 4B regimen for retreated cases [6 Z E 
Cm Lfx Pto Cs (PAS)/12 Z E Lfx Pto Cs (PAS)] [4]. Many 
non-GLC patients, received regimens 4A or 4B, except 
Prothionamide was replaced by Ethionamide (Table  1). 
One possible explanation for this difference is that Pro-
thinamide is more difficult to obtain in private phar-
macies than Ethionamide, and that the efficiency of the 
two drugs is comparable. Most treatment regimens con-
tained five drugs in the intensive phase, with the inject-
able drug being ceased in the continuous phase. Among 
the five drugs used in the intensive phase, the regimen 
always included injectable drugs (most often Amikacin/
Kanamycin, with a few regimens including Capreomycin 
instead). One drug belong to fluoroquinolone group; (in 
decreasing frequency of used: Ofloxacin/Levofloxacin/
Moxifloxacin/Gatifloxacin/Ciprofloxacin). Most regimen 
included Ethionamide. The fourth drug was either cyclo-
serine or PAS, in order of decreasing frequency of use. 
Many regimens used both Cycloserine and PAS. And the 
last drug included in standard regimens was the first line 
drugs (Pyrazinamide/Ethambutol).
In this study, 47 % of patients taking GLC drugs reported 
adverse reactions and 52 % of non-GLC patients reported 
adverse reactions. However, the lower compliance in non-
GLC patients (or higher of defaulter rate) may have reduced 
the likelihood of documented adverse events in this group. 
This was consistent with the opinion of doctors, that there 
was no significant difference in the rate of adverse reactions 
between GLC patients and non-GLC patients.
The frequency of adverse reactions in this study was 
quite low in comparison to other studies. Among 2027 
MDR-TB patients enrolled from 2000 to 2004 in Lat-
via, 807 (79  %) experienced at least one adverse event 
[5]. In study in Tomsk, Russia, of 244 MDR-TB patients 
enrolled from September 2000 to 2002, 73 % had experi-
enced at least one adverse event [6]. A study of 38 MDR-
TB patients in India in the years 2006–2007 showed that 
58  % patients reported adverse drug reactions which 
required dose reduction or termination of the offending 
drug [7]. Another study was collected data on adverse 
events from five DOTS-Plus sites in Estonia, Latvia, Peru 
Table 3 Frequency of adverse drug events observed during MDR treatment, Pham Ngoc Thach hospital, 2010
a  An individual patient could have had more than 1 adverse event during the MDR treatment period
b  Mild: the drug was continued at the same dose, with or without ancillary drug prescribed, e.g., reassurance
c  Moderate: drug was continued at a reduced dose, with an ancillary drug prescribed
d  Severe: drug was changed or stopped and/or all medical treatment was stopped
Type of adverse eventa Total Mildb Moderatec Severed No information
n %
Total 226 100.0 78 32 25 91
Arthralgia/joint pain 81 35.8 25 16 7 33
Gastrointestinal 32 14.2 18 2 0 12
Ototoxicity 19 8.4 8 3 4 4
Cutaneous reaction 15 6.6 4 4 0 7
Giddiness 13 5.8 2 1 0 10
Psychiatric symptoms 10 4.4 5 1 3 1
Hepatitis 7 3.1 1 2 4 0
Peripheral neuropathy 7 3.1 3 1 0 3
Renal toxicity 5 2.2 2 0 3 0
Visual symptoms 5 2.2 4 0 0 1
Insomnia 5 2.2 0 0 0 5
Hypothyroidism 3 1.3 0 2 1 0
Central nervous system 1 0.4 0 0 0 1
Others 23 10.2 6 0 3 14
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(Lima), the Philippines (Manila) and the Russian Federa-
tion (Tomsk Oblast), the results showed that among 818 
MDR-TB patients, only 2  % of patients stopped treat-
ment, but 30 % required removal of the suspected drugs 
from the regimen due to adverse events [8].
The most common adverse drug reactions were also 
observed varies between published studies. In Nathanson 
et al., the five most common adverse events were nausea/
vomiting (33 %), diarrhea (21 %), arthralgia (16 %), dizzi-
ness/vertigo (14 %) and hearing disturbances (12 %) [8] [5]. 
In another Latvian study, the mostly commonly reported 
event were nausea (58  %), vomiting (39  %) and abdomi-
nal pain (24 %) [5]. Another study in Turkey review of the 
medical records of 263 MDR-TB patients reported that 
69 % had side effects, most frequently ototoxicity (42 %); 
psychiatric disorders (21 %); arthralgia (11 %) and epileptic 
seizures (10 %) [9]. In our study, the most common adverse 
drug reactions were arthralgia or joint pain (36  %), fol-
lowed by gastrointestinal disturbance (14 %).
An important implication of this study is the impor-
tance of ensuring that staff within the NTP are trained 
to recognize and manage common adverse events associ-
ated with use of SLDs.
To our knowledge, this is the first study to describe 
the incidence of adverse drug reactions among MDR-TB 
patients in Vietnam. Our study has limitations. Firstly, 
this is retrospective study, based on information in the 
patient’s files of the cohort of GLC and non-GLC patients 
treated in PNT hospitals in the year 2010, so that we only 
have information if it available in patient files. Secondly, 
the study did not use standardized definitions of adverse 
events, their diagnosis or the severity, this may lead to the 
frequency and severity of events being reported in a vari-
able fashion. Lastly, since the program’s rules forced cer-
tain patients to choose the non-GLC option (those who 
lived outside HCMC or could not afford to be admitted 
to the hospital), the comparison in this study is not really 
an evaluation of GLC drugs or the GLC program, but a 
comparison between two different groups of patients.
Conclusions
In conclusion, there are many perceived disadvantages 
of taking non-GLC treatment among patients attending 
PNT hospital in HCHC, Vietnam. These patients require 
greater support from the NTP to complete MDR treat-
ment and improve their treatment outcomes. Training on 
management of adverse drug reactions for health staff is 
also needed.
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